Side effects
There was no general toxicity during or after drug injection. Headache (typically tolerable was observed in some patients receiving VM26 or BCNU. Seizure developed in 2.7% of the patients receiving VM26 or BCNU. ACNU did not cause discomfort in any patient ( Table 1) . The Li Anmin I reservoir has several advantages over Ommaya reservoir. First, the extracranial capsule of the new reservoir has a steel or titanium basement plate, which prevents it from being pierced during the drug injection. Second, the tube of the new reservoir extends from the side of the external capsule rather than from the bottom as in the Ommaya reservoir [8, 9] . This new configuration facilitates fixation and reduces the capsule volume. Overall, hawse has achieved positive therapeutic outcomes with tolerable adverse effects with this method. As a result, it is now widely adopted in China. 
Selective/super-selective interventional chemotherapy via the cerebral artery
In early 1990s in China, interventional therapy via the cerebral artery was primarily a tool for the diagnosis and treatment of cerebrovascular diseases. In 1993, the authors presented the first use of interventional chemotherapy via cerebral artery for the treatment of MG.0
Methods
There are three major methods currently used by the authors in the cerebral interventional chemotherapy (Fig. 3 ): intervention by common carotid artery, intervention by femoral-internal carotid (supraclinoid)/vertebrobasilar artery (selective chemotherapy), and intervention by femoral-tumor feeding artery (super-selective chemotherapy). 
Side effects
From Apr 1991 to Dec 2008, 677 patients received this therapy, and 4916 operations were performed. The side effects for interventional chemotherapy included three cases of vision reduction, perhaps due to embolism of retinal arteriole by chemotherapeutic microlipoparticles, one case of hemiplegia caused by breaking off of the plaque in the bifurcation and embolized of ICA during the punctuation of CCA. Leucopenia and thrombocytopenia developed in 92 cases (24.4%), but recovered within four weeks of withdrawal in most cases. In seven cases, white blood cell count was too low to continue the chemotherapy. Spontaneous hemorrhagic tendency (the thrombocytopenia after chemotherapy had no effective treatment to promote the recovery of bone marrow function) occurred in two cases. Myelofibrosis was observed in one case. Cerebral artery interventional chemotherapy significantly reduced the adverse effects of chemotherapeutic agents and elevated the intratumoral local drug concentration by more than 15-fold (Fig. 4) . From 2001 to 2008, 283 of 379 cases were treated with interventional chemotherapy, and 158 cases (56.0%) had favorable outcomes. This method has been adopted widely (Fig. 5 ).
Typical case:
MRI after first surgery MRI after second surgery MRI of glioma recurrence CT after 8-month chemotherapy 
High dose chemotherapy supported by Autologous Peripheral Blood Bone Marrow Stem Cell (APBBMSC)
Based on the dose-effect curve of chemotherapeutic agents, the authors used high-dose chemotherapy (twice the normal dose) to treat MG. In 2003, we introduced APBBMSCsupported high-dose chemotherapy for MG. Beginning at five days before chemotherapy, 300 µg of granulocyte colony stimulating factor (G-CSF) was injected daily to stimulate APBBMSCs. The APBBMSCs were isolated from peripheral blood and concentrated in a 60 mL suspension. The cell concentration was adjusted to 1.0 × 10 9 cells/mL with Tc-199 cell culture solution blended with buffer solution (60% Tc-199, 20% dimethyl sulfoxide, 20% autologous plasma). APBBMSC was stored in liquid nitrogen. After the high-dose chemotherapy, frozen APBBMSCs were thawed rapidly at 4ºC and administered intravenously at 48-72 h post-chemotherapy (Fig. 6 ). In this series, the overall effective rate was 55.6% (total number of patients: 27; 2 CR cases, 13 PR cases, 10 MR cases, 1 NC case, and 1 PD case; Fig. 7 ).
Typical case:
MRI before treatment MRI after 21-month treatment This study indicated that APBBMSC-supported high-dose chemotherapy offers the advantage of rapid recovery of bone marrow after high-dose chemotherapy. Compared with bone marrow transplants following chemotherapy, APBBMSC-supported high-dose chemotherapy is easy to perform and could achieve rapid recovery of hematopoietic function with limited side effects [10] .
Intra-tumoral brachytherapy
In 1993, the authors developed a radiotherapy reservoir (Li Anmin II reservoir, Fig. 8 -A) to perform postoperative intra-tumoral brachytherapy for MG. This treatment was used in 172 of the 379 patients.
Methods
After surgical removal of the tumor, a brachytherapy reservoir was implanted into the residual tumor cavity, and the valve of the reservoir was embedded subcutaneously (Fig. 8-B ). Radioactive isotopes ( 125 I or 131 I) were injected through the reservoir valve into the www.intechopen.com
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reservoir. The reservoir formed an oval-shaped radioactive envelope (Fig. 9) , and produced localized, long-term, high-dosage irradiation to the residual cavity and the surrounding region for two half lives ( 125 I t 1/2 =120 days and 131 I t 1/2 =16 days). 
247
The isotopes emited high-energetic particles to damage the ultra micro-structure of DNA in MG cells. Simultaneously, hyperplasia of vascular endotheliocytes was induced, reducing blood supply to the tumor. According to the radiometric determination from the water and wax model, brachytherapy produced a 3-to 5-fold larger absorption than routine extracranial irradiation of 10-20 cGy/h. These results are in accordance with Gutin's report. To measure the radioactivity absorbed in the remnant tumor, we used an radioactivity detector (NE Company UK Ionex 2500/3) and a finger-shaped ionization chamber. Calculation using the formula Or = 51. The extent of brain edema in normal brain tissue was lower than that after routine radiotherapy. Light and electron microscopy of brain tissue samples from a patient treated by intra-tumoral brachytherapy revealed that there was no tumor growth within 3 cm of the implanted radioactive source and that tumor cells 4 cm from the source were inactive. This treatment offers several advantages over routine radiotherapy. First, the isotope was much closer to the residual tumor cells (Fig. 10) . As a result, efficacy was improved; toxicity was reduced. Second, the isotope was sealed within the reservoir without leakage into the body. Third, survival time and quality of life improved in this treatment compared to the control group. The survival time increased with increasing radioactive dose. Finally, according to tumor proliferation during treatment, when patients need additional treatment, the reservoir can be refilled with the radioactive isotope through the subcutaneous valve.
Typical case:
Postoperative CT scan before treatment CT after 2-year treatment. The patient is still alive. This therapy involves three primary mechanisms ( Fig. 13 ). First, a high-energy liquid radioactive source was placed at the interface of tumor and normal brain tissues, preventing the tumor from invading deep structures. Second, the liquid isotope flowed out of the reservoir into the interstitial fluid, irradiating tumor cells during the regeneration of the interstitial fluid. Finally, the liquid radioactive agents within the reservoir tube formed a radioactive column inside the tumor, subjecting it to continuous radiation for >16 d (2 half lives of 131 I). The 131 I fluid can be refilled to prolong the radioactive exposure.
www.intechopen.com 
Complications and prevention
Hypothyroidism is a common complication in patients receiving long-term, cumulative exposure to micro-doses of 131 I, but could be prevented by iodine treatment prior to and during the exposure.
Immunologically targeted radiotherapy via monoclonal antibodies (McAb) loaded with 131 I
Immunologically targeted radiotherapy was designed for targeted brachytherapy [11] . Due to the weak immunogenicity and heterogeneity of glioma cells, an anti-nucleus McAb loaded with 131 I works better than an anti-membrane antibody. The chimeric McAb binds specifically to histones inside the dying tumor cells to destroy the adjacent tumor cells with high-dose local irradiation (Fig. 15) . In collaboration with Epstein at the Department of Pathology, University of Southern California, the authors completed a phase II clinical trial in 56 MG patients in China. Of the 56 patients, 37.5% showed marked improvement and 42.8% showed mild improvement. The 1-year survival rate was 92.8%. The recommended intrathecal administration resulted in accumulation of radioactive isotopes in the subarachnoid space and cerebral cistern rather than in the tumor tissue (Fig. 16) . Additionally, intrathecal administration induced adverse effects on thyroid and bone marrow.
By contrast, when drugs were administered to the tumor via the Li Anmin I reservoir, the adverse effects on the thyroid and bone marrow were reduced (Fig. 17) . 
Typical case:
Before treatment 7 years after treatment In a follow-up of 1-3 yr, tumor control was seen in all cases. In 4 cases, the tumor disappeared. Shrinkage of the tumor was seen in 7 cases and maintained in 6 cases for 6-12 months. In the remaining 4 cases, tumor size remained stable for 1 year.
Methods
The treatment consisted of surgery and postoperative brachytherapy. For brain stem MG, the occipital squama and posterior arch of the atlas were removed. In spinal cord MG, laminectomy was performed for decompression in the two adjacent normal vertebral plates. Biopsies were conducted as needed. The intra-tumoral sack of the reservoir (Li Anmin I reservoir) was implanted near the tumor (Fig. 18) 
Efficacy
Brachytherapy has the advantages of localized high-absorption, long treatment cycles, and low radioactive injury to normal neural tissue, and therefore is suitable for patients with MG the brain stem or spinal cord [12, 13] . The 15 patients receiving this therapy exhibited improved short-term and long-term survival. Two patients survived for >3 years. Posttreatment MRI revealed that all primary tumors were under control or in partial remission (Figs. 19 and 20 ).
Typical case: 
Clinical application of new regional tumor therapy
Traditional treatments ignore the fact that MG is a localized tumor and target the entire body or the entire brain. Such treatments impair the immune and hemotopoeitic systems, and drastically reduce the quality of life. Based on pathogenesis, proliferation, pathological types, recurrence mode, and age at onset, MG is classified into six categories: primary glioma, recurrent glioma, cystic glioma, glioma in functional zones, low-grade glioma, and brain stem/spinal cord glioma.
With the goal of improving the quality of life for MG patients, the authors developed seven new regional therapeutic methods. Long-term therapeutic plan was individualized for each patient. Intra-tumoral brachytherapy and selective/super-selective interventional chemotherapy were commonly used in combination in our practice. A second common treatment combination included brachytherapy, intra-tumor interstitial chemotherapy, and selective/super-selective interventional chemotherapy via cerebral artery. (Table 2) . Table 2 . Clinical treatments of the six MG categories.
The overall 1-year, 2-year, and 3-year survival rate in our patients was 65.0%, 47%, and 16.6%, respectively. The tumor completely disappeared in 6.3% of the patients. This outcome is significantly better than previously reported (Table 3) . 
Magnetic targeting chemotherapy against brain gliomas
One of the major problems in chemotherapy f o r M G i s t h e l a c k o f p e r m e a t i o n o f chemotherapeutic drugs through the BBB and tumor cell membrane. These difficulties may be overcome by novel delivery methods. For example, we developed a magnetic targeting drug delivery system between 1995 and 2008 (Fig.21) . We conducted a series of experiments to examine the distribution, efficacy, and potential toxicity of this system. Results are summarized below. 
Toxicity of magnetic drugs on liver, kidney, and bone marrow

Methods
Sixty Kunming mice were randomly divided into three groups, and received different drugs in the presence or absence of an external magnetic field (Table 4) . RBC, WBC, PLT, alamine aminotransferase (ALT), and blood urea nitrogen (BUN) were measured prior to and at 1, 7, 14, 30, and 90 d after the treatment. Table 4 . Toxicity profile.
Groups
Results
RBC, WBC, and PLT counts in the MTX group decreased significantly after the treatment, reached the lowest levels at 14 d post-injection and recovered after 90 d. In the magnetic targeting group, the RBC count was lowest at 7 d post-injection and gradually recovered after 90 d. Remarkable difference was found among three groups, as shown in Fig. 22 , demonstrating that magnetic targeting can reduce the toxicity of chemical drugs on bone marrow. Changes in ALT and BUN levels reflected the hepatic and renal injury. The magnetic targeting group had markedly lower ALT and BUN levels compared to the MTX group, indicating that magnetic targeting can reduce the side effects of chemotherapeutic drugs and protect the liver, kidneys, and bone marrow from systemic chemotherapy [14] . 
Distribution of the magnetic drugs in the brain
We investigated the distribution of magnetic drugs in the brain under magnetic drug targeting and explored magnetic targeting chemotherapy for malignant brain tumors.
Methods
Ninety SD rats were divided into three groups, and received different drugs in the presence or absence of an external magnetic field (Table 5 ). Ten rats from each group were randomly selected for sacrifice at 15 min intervals after drug injections. MTX levels in both sides of brain of each rat were measured. Table 6 . MTX concentration in the brain hemispheres.
Groups
Conclusions
Under magnetic targeting, magnetic drugs accumulated in the targeted area in the brain and local drug concentrations increased by 2-9 folds.
Drug delivery by Superparamagnetic Paclitaxel Nanoparticles (SPPNPs)
Preparation and characteristics of SPPNPs 13.1.1 Methods
SPPNPs were synthesized with octadecyl-quaternized carboxymethyl chitosans and Fe 3 O 4 ferrofluid, cholesterol, and paclitaxel at a weight ratio of 4:3:3:2 by reverse-phase evaporation. The diameters, magnetism, and drug release rates of the SPPNPs were examined with transmission electron microscope (TEM), a vibrating sample magnetometer (VSM), and high performance liquid chromatography (HPLC).
Results
TEM revealed an average diameter of ~20 nm with a narrow size distribution. The VSM analysis indicated that the paclitaxel nanoparticles were superparamagnetic (Fig. 23) . The drug release test showed sustained drug release for >15 days (Fig. 24) .
Cellular study 13.2.1 Methods
We examined intracellular distribution of FITC-labeled SPPNPs in MG cell line C6 under a fluorescent microscope. Cytotoxicity and apoptosis-inducing capacity of SPPNPs were also examined using CCK-8 kit and flow cytometry, respectively.
Results
The nanoparticles were taken up by the glioma cells. Confocal microscopy showed that these nanoparticles are present in the cytoplasm. C6 Cells were incubated with magnetic paclitaxel nanoparticles containing 1-80 nM paclitaxel or free paclitaxel of the same concentrations for 6-24 h. Both free placlitaxel and magnetic paclitaxel nanoparticles inhibited the proliferation of C6 cells in a dose and time-dependent manner. Cytotoxicity was comparable between free paclitaxel and paclitaxel released from the magnetic nanoparticles (Fig. 25) . . After an external magnet was placed, the nanoparticles were attracted to the container wall (E). Vibrating sample magnetometry showed that these nanoparticles were superparamagnetic (F). 
Animal experiments 13.3.1 Drug concentration in rat brains after magnetic targeting
Male Wistar rats were randomly assigned into three groups, and received SPPNPs or PTX in the presence or absence of an external magnetic field (Table 7) .
Groups Drug External Magnetic Field
Magnetic targeting SPPNP (2.5 mL/kg) 0.5T, across head Non-magnetic targeting SPPNP (2.5 mL/kg) without Control PTX (1.0 mg/mL) without Table 7 . Treatment conditions in rat experiments.
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The brain tissues were harvested at 1, 4, 8, and 16 h post-injection. PTX concentration was measured by HPLC.
Results
After intravenous injection of SPPNP, the PTX concentration in the non-magnetic targeting group was significantly lower compared to the magnetic targeting group, but markedly higher than that in control group (Fig. 26) .
Inhibition of glioma cells in tumor-bearing rats after SPPNP injection and magnetic targeting
Methods
C6 cells were implanted into the rat brain stereotactically. After emergence of brain tumor symptoms, rats were divided into three groups. They were treated as shown in the following Table 7 .
Results
The effect of free paclitaxel or the SPPNPs on the survival of rats bearing C6 glioma was depicted in Fig. 5 . We found that the rats that received free paclitaxel at 10 mg/kg had a median survival of 12 d and a mean survival of 13.6 d (Tab. 2). The rats that received the magnetic paclitaxel nanoparticles and magnetic targeting had a median survival of 27 d and a mean survival of 27.4 d with the longest survival at 34 d, whose survival time increased for 1.5 times compared to those who received free paclitaxel (Fig. 27) . 
Conclusion
SPPNPs are safe and stable vectors to release chemotherapeutic drugs [15] . The small size allows SPPNPs to enter tumor cells. In the presence of an external magnetic field, SPPNPs can accumulate in magnetic targeted area [16, 17] . This treatment inhibited tumor growth and prolonged the survival of glioma-bearing rats.
Possible mechanisms of magnetic targeting therapy against MG 1. Increase localized drug concentration
In the presence of an external magnetic field, magnetic chemotherapeutic drugs move within capillaries in the targeted areas of the brain and tumor. This increases the local drug concentration dramatically both around the tumor region and in the blood vessels of magnetic field [18] . Our results showed that magnetic targeting could increase the local drug concentration by 2-15 folds.
Slow release of loaded drugs
In the magnetic targeted area, the biodegradable capsule of magnetic drugs constantly degrades, slowly releasing the drugs into the vasculature or interstitial space of tumors or inside the tumor cells. This slow-release produces a sustained inhibition of the tumor cells.
Thrombosis by magnetic particles
Neoplastic deformation of tumor vasculature and ferrofluid in the magnetic field may facilitate the formation of micro-thrombi in the tumor capillary vessel and microvessel, and decrease the blood supply to the tumor [19] .
Improve the penetration across biological membrane
The penetration of drugs across BBB depends on the local concentration gradient across the brain endotheliocytes. Magnetic targeting increases the drug content in the interstitial fluid of tumor. In addition to this concentration gradient, the strong magnetic field promotes the movement of the magnetic drug into the tumor from the capillary vessels and microvessels. Permeability and endocytosis permit the magnetic particles and chemotherapeutic drugs to enter the tumor cells [20] .
Magnetic-chemotherapeutic effects of magnetic particles
The magnetic particles and external magnetic field may have synergistic action. In traditional Chinese medicine, magnetite has been used to generate magnetic field in tumor patients. In magnetic targeting therapy, the encapsulated ferrofluid can generate the magnetic-chemotherapeutic antineoplastic effects [21] .
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